. The mTORC1 and IFN- production defects were partially rescued by supplementation with glutamine, which requires CARD11 for import into T cells. Our findings indicate that a single hypomorphic mutation in CARD11 can cause potentially correctable cellular defects that lead to atopic dermatitis.
Monogenic causes for immune disorders have provided critical insight into the role of specific immune pathways in the pathogenesis of common diseases, including atopy and allergic diseases. In the case of some allergic disorders involving atopic dermatitis and elevated IgE coupled with infection, it may be difficult to distinguish the contribution of impaired host defense from that of the defined genetic lesion in allergic disease. Severe atopic disease and elevated serum IgE levels have now been linked to mutations in immune-mediated host defense pathway genes, including DOCK8, STAT3 and PGM3 (refs. [1] [2] [3] . In some patients with severe atopic dermatitis, elevated IgE and eosinophilia, infections beyond the skin are less common and they lack comorbidities seen with the genetically defined disorders, so there is little reason to suspect an immune deficiency. Reports of single gene mutations in common allergic disease without overt syndromic features have been rare 4 , but examples are increasingly described. One such example is a single gain-of-function (GOF) mutation in IL4RA, identified initially in a few severely atopic patients 5 , that is a common risk allele in allergic disease 6 . Another is loss-of-function (LOF) mutations in IFNGR1 leading to atopic dermatitis with eczema herpeticum without additional immune phenotypes 7 . LOF mutations in cytokine signaling components such as STAT3 and STAT5B 8 can also contribute to atopic phenotypes with substantial multisystem comorbidity, seen also in putative antigen receptor signaling gene mutations such as WASP, DOCK8 (ref. 9 ) and MALT1 (ref. 10) . Diminished antigen-driven TCR signaling can predispose to type 2 helper T cell (T H 2) phenotypes in a variety of in vivo and in vitro settings 9 , and mouse models have shown that hypomorphic mutations in ZAP70 (ref. 11 ) and CARD11 (ref. 12) can also lead to severe atopy.
CARD11 (also known as CARMA1) encodes a membrane-associated guanylate kinase (MAGUK) family protein that partners with BCL10 and MALT1 to form the CBM complex, a scaffold classically required CARD11 mutations interfere with NF-B and mTORC1 activation The four heterozygous mutations detected in the patients affect markedly different domains of the CARD11 protein (UniProtKB Q9BXL7) ( Fig. 1b) . L194P and dup183_196 are found in the coiled coil (CC) domain. E57D is in the N-terminal CARD domain, and R975W is in the C-terminal GUK domain. None were found in public polymorphism databases (for example, ExAC). Notably, Goodnow and colleagues noted elevated IgE levels and severe eczema in the Card11 unm (UNM) mouse strain, which harbors an ENU-mutagenesis-induced, homozygous Card11 mutation in the CC domain (p.Leu298Gln), raising the possibility that the patients' CARD11 mutations might lead to hypomorphic activity 12 . However, UNM heterozygote mice had no atopic phenotype, and the heterozygous parental carriers of patients with CARD11-associated severe combined immunodeficiency (SCID) were reported as clinically asymptomatic 14, 15 and did not have a history of atopy (A. Kulozik and P. Stepensky, personal communication), suggesting that haploinsufficiency was not a likely explanation for the patients' presentation ( Fig. 1c) .
Two principal signaling pathways in which CARD11 participates are NF-κB [21] [22] [23] and, identified more recently, mTORC1 (refs. 24,25) . We first assessed the effect of the four CARD11 mutations on NF-κB activation by transfecting wild-type and mutant CARD11 expression constructs into a CARD11-deficient Jurkat T cell line (JPM50.6) expressing a NF-κB-driven GFP reporter. As shown previously, the GOF mutant E134G, described in a family with BENTA disease, induced constitutive GFP expression in the absence of antigen receptor (AgR) ligation 18, 19 (Fig. 2a) . When compared to wild type, all four CARD11 mutants induced little NF-κB activation upon stimulation with anti-CD3 and anti-CD28, confirming loss of function ( Fig. 2a,b Family A (L194P) (ND) Fig. 1a ). Furthermore, co-transfection of each mutant construct disrupted the ability of wild-type CARD11 to activate NF-κB ( Fig. 2c-e and Supplementary Fig. 1b ), suggesting dominant interference; the R975W mutant was least disruptive.
Notably, disruption of NF-κB activation by wild-type CARD11 was not observed in co-transfections with empty vector, E134G or Q945X, a homozygous, functionally 'null' nonsense mutant described in an autosomal recessive SCID patient born to healthy, heterozygous parents 14 (Supplementary Fig. 1c-h) . Similar results were obtained upon transfection of Jurkat T cells expressing endogenous wild-type CARD11, as measured by an NF-κB-dependent luciferase assay (Fig. 2g,h and Supplementary Fig. 1i ). All mutants were comparably expressed in transfected cells ( Fig. 2) . Next, we examined mTORC1 activity by measuring phosphorylation of ribosomal protein S6 (p-S6) and found that all four hypomorphic CARD11 mutants resulted in significantly decreased mTORC1 activity at baseline (unstimulated) and upon anti-CD3 and anti-CD28 stimulation in Jurkat T cells ( Fig. 2i,j and Supplementary Fig. 1j ). Similar attenuation of p-S6 signaling was noted for each mutant, compared to cells transfected with ectopic wild-type CARD11 or empty vector, suggesting interference with endogenous wild-type CARD11 ( Fig. 2k and Supplementary Fig. 1j ,k). Q945X expression had little effect ( Supplementary Fig. 1l ). Taken together, these findings show that each CARD11 mutant is hypomorphic and reduces wild-type CARD11 activity in a heterozygous context, as illustrated by decreased downstream activation of both NF-κB and mTORC1.
Defective NF-κB activation is probably a result of impaired CBM complex assembly, as we observed substantially less association of CARD11 LOF mutants with BCL10 and MALT1 in JPM50.6 co-immunoprecipitations (co-IPs) after phorbol 12-myristate 13-acetate (PMA)-ionomycin stimulation (Fig. 3a) . In fact, we recovered less CARD11 in BCL10 co-IPs from wild-type Jurkat cells transfected with CARD11 E57D, suggesting that assembly of the endogenous CBM complex was disrupted ( Fig. 3b) . Consistent with dominant interference, MALT1 protease activity, as measured by cleavage of the MALT1 substrate CYLD 26 , was also diminished in Jurkat T cells in the presence of CARD11 LOF mutants ( Fig. 3c,d) .
CARD11-mutant patient T cells show low activation responses
We next investigated CARD11-dependent signaling in primary patient T cells. PMA stimulation of patient lymphocytes revealed marked impairment of NF-κB activation, as indicated by reduced p65 phosphorylation and IκB degradation in T cells from families A, B and C ( Fig. 3e) . Similarly, mTORC1 activity (indicated by p-S6) was also attenuated in stimulated patient cells ( Fig. 3e and Supplementary Fig. 2 ), whereas phosphorylation of AKT at S473 (a readout of mTORC2) was normal ( Fig. 3e) . Reduced p38 activity was also noted in some patient cells ( Fig. 3e) , whereas robust ERK activity was comparable across all subjects, consistent with normal ERK activity noted in the UNM mice 12 . Patient B-I, who harbors the R975W alteration, which had the lowest NF-κB inhibitory activity, and who had the fewest comorbidities beyond atopy, had recently been treated with corticosteroids and methotrexate when blood was drawn, potentially complicating the assessment of T cell phenotype and function. Of note, milder NF-κB and mTORC1 signaling defects could also be detected in CD19 + B cells from some patients ( Supplementary Fig. 3a) . Overall, B cell development was generally unaffected in these patients ( Supplementary Fig. 3b,c) .
We also observed poor upregulation of key cell surface markers such as CD69, CD25 and CD98 after overnight stimulation with anti-CD3, particularly for patient A-I ( Fig. 4a ). Both peripheral blood mononuclear cells (PBMCs) ( Fig. 4b , left) and sorted naive T cells ( Supplementary Fig. 4a ) from patient A-I showed decreased short-term proliferation upon anti-CD3 and anti-CD28 stimulation. PBMCs from subject B-II.2 also showed mildly decreased blastogenesis upon stimulation ( Fig. 4b, middle) , and subjects D-I, D-II.1 and D-II.2 showed a moderate defect ( Fig. 4b, right) . These data indicate that the activation and proliferation of CARD11-mutant patient T cells were variably impaired, consistent with defective activation of NF-κB and mTORC1.
Further flow cytometric phenotyping of patient PBMCs showed variability in CD45RA − memory T cells and circulating CXCR5 + PD-1 hi follicular helper T (cT FH ) cells in families A-C ( Fig. 5a and Supplementary Table 1 ). Direct ex vivo ( Fig. 5b and Supplementary  Fig. 4b ) and 5-d culture ( Supplementary Fig. 4c ) of patient T cells showed impaired T H 1, normal interleukin 17-producing T helper (T H 17) cells and elevated T H 2 cytokine production within the CD45RO + compartment, mirroring the phenotype of UNM mice and, with the exception of IL-17 production, mice lacking mTORC1 and ASCT2 (refs. [27] [28] [29] [30] . Numbers of CD4 + FOXP3 + regulatory T cells, whose diminished frequency is thought to contribute to the UNM mouse phenotype 31 , were normal in all subjects ( Fig. 5c and A r t i c l e s Supplementary Table 1 ). The percentage of dividing regulatory T (T reg ) cells (Ki-67 + ) was also comparable to controls ( Fig. 5c ), as was their frequency and suppressive function ( Supplementary Fig. 5 ).
However, aberrant co-expression of GATA3 in T reg cells from patients
A-I and B-I suggests impaired GATA3 regulation ( Fig. 5d) , a finding associated with atopy in a variety of settings 32, 33 . Collectively, these results indicate that patient T cells harboring CARD11 LOF or dominant-negative (DN) mutations are hyporesponsive and skew toward a T H 2 phenotype, consistent with their atopic predisposition.
CARD11 mutations result in poor upregulation of ASCT2
CARD11 was recently shown to be critical for mTORC1 activation 25 , at least in part as a facilitator of T cell antigen receptor (TCR)-induced upregulation and/or activation of ASCT2, an essential glutamine transporter required for extracellular glutamine import during cellular activation 24 . Similarly to CARD11-deficient murine T cells 24 , CARD11-mutant patient T cells showed reduced ASCT2 upregulation after TCR activation ( Fig. 5e and Supplementary Data). Mice lacking ASCT2 also show defects in mTORC1 activation, impairments in T H 1 differentiation and a T H 2-skewed phenotype 30 . However, the addition of exogenous glutamine could rescue mTORC1 signaling and reverse T H 1 defects 24 . Supplementing culture medium with exogenous glutamine boosted mTORC1 activation (p-S6) in patient A-I T cells, particularly in CD45RA + naive T cells ( Fig. 6a,b) , without affecting NF-κB or ERK phosphorylation (data not shown). We then cultured naive patient A-I T cells in the presence of supplemented glutamine A r t i c l e s (3 mM) under a variety of stimulation conditions. We found that combinations of cytokines capable of activating NF-κB (IL-1β and TNF) and STAT3 (IL-6) partially rescued defects in proliferation and CD98 induction, but only with exogenous glutamine supplementation (Fig. 6c,d and Supplementary Fig. 6 ). While these conditions are not ideal for measuring biases for cell-intrinsic T H cell differentiation, we did find that divided cells were more likely to produce IFN-γ upon glutamine supplementation (Fig. 6e) . Together, these results suggest that T cell responses in these patients might be partially restored simply through glutamine supplementation.
DISCUSSION
Here we show that different heterozygous hypomorphic mutations in CARD11 can lead to severe atopic disease in humans, associated with weaker, T H 2-skewed T cell responses. These subjects mostly lack the nonimmunologic features seen in PGM3, STAT3 and DOCK8 deficiencies, but share features of severe atopic dermatitis, often with elevated serum IgE levels and peripheral blood eosinophilia. A similar atopic disease phenotype in UNM mice, which are homozygous for a hypomorphic Card11 mutation, provides strong evidence for the association of hypomorphic CARD11 activity and atopy 12 . However, in contrast to observations in UNM mice, our results demonstrate that the four unique CARD11 LOF mutations found in our patient cohort can dominantly interfere with wild-type CARD11 signaling, providing autosomal dominant inheritance with variable penetrance. In addition to identifying a new cause of an inherited syndrome associated with atopic dermatitis, peripheral blood eosinophilia and elevated IgE, these findings raise the possibility that dominant-negative CARD11 mutations could be a common cause of severe allergy in the absence of syndromic features. Heterozygous CARD11 mutations should therefore be considered in genetic testing of families with autosomal dominant inheritance of a history of significant atopic dermatitis (current or remote), elevated IgE and eosinophilia independent of other comorbidities.
The scaffold function of CARD11 in lymphocytes is normally tightly regulated, ensuring that formation of the CBM complex and downstream signaling are triggered only after antigen-receptordependent phosphorylation of the inhibitory linker domain [34] [35] [36] . Two of the CARD11 alterations in patients were located in the CC domain, a demonstrated hot spot for GOF and LOF mutations, which probably perturb intramolecular regulation via the linker, thereby enhancing or debilitating self-oligomerization of CARD11 required for signalosome assembly, respectively 37 . Similarly, it is likely that the E57D alteration in the CARD domain directly disrupts interaction with BCL10, a key initiating event in CBM signaling. The importance of CARD and CC domain protein interactions for nucleating the larger CBM signalosome probably explains the substantial reduction in CBM complex formation and NF-κB activation observed in transfected cells. In contrast, the unusual MAGUK domain alteration R975W may interfere with higher-order, intermolecular 'clustering' of activated CARD11 molecules via SH3-GUK interactions 38 , explaining a weaker dominant-negative effect on NF-κB stimulation (Fig. 2e) . Indeed, a lesser NF-κB defect associated with this specific GUK domain variant may help explain the milder infectious disease history and cellular phenotypes observed in family B. In contrast, the LOF and DN activity we observed in relation to mTORC1 signaling was comparable for all four CARD11 mutants in transfection studies, suggesting more discrete roles for the NF-κB and mTORC1 pathways in preventing infection and atopy, respectively. It remains unclear which CARD11 domains might be required for direct interaction and/or transcriptional regulation of ASCT2, the glutamine transporter connecting AgR engagement with mTORC1 activation 24, 25 . Attenuated p38 signaling in some CARD11-mutant patient cells was surprising, as CARD11 has not been specifically implicated in this MAPK pathway. Given that the MAGUK protein DLGH1 governs the TCR-driven "alternative p38 pathway" 39 , perhaps these CARD11 mutants interfere with related MAGUK family scaffold proteins in as yet undefined ways. 
A r t i c l e s
Problems with T cell proliferation and balanced T H cell differentiation in the CARD11-mutant patients probably result from defects in multiple TCR-driven signaling pathways that rely on CARD11. Disruption of TCR signal strength, which can occur in a variety of settings and TCR signaling pathways, has been associated with T H 2 bias 40 , and this phenomenon probably contributes to the pathogenesis of these patients. Numerous studies have shown that disruption of NF-κB or mTORC1 signaling blocks proper T cell expansion, probably by compromising both the interleukin 2 (IL-2) signaling loop and metabolic reprogramming required for T cell proliferation. For these reasons, it was difficult to definitively characterize the effect of these CARD11 LOF mutations on T H cell differentiation, as typical unbiased in vitro conditions did not support T cell proliferation. However, recent work indicates that mTOR activity profoundly affects T H cell differentiation 41 . The attenuation of CARD11-dependent mTORC1 activation ostensibly contributes to impaired T H 1 differentiation in our patients, allowing an mTORC2-dependent T H 2 response to dominate. NF-κB signal blockade in mouse T cells was also shown to preferentially disrupt the T H 1 response and permit T H 2-driven allergic inflammation in vivo 42 . Whether reduced (but not absent) A r t i c l e s IFN-γ production explains the atopic and skin infection phenotype entirely, as suggested in patients with hypomorphic IFNGR mutations, is not clear. An intrinsic T H 2 bias alone could drive the atopic phenotype and predispose to skin infection 43 .
Recent work suggests CARD11-dependent NF-κB stimulation is particularly important for T H 17 differentiation of mouse T cells in vitro under specific polarizing conditions 44 . In vivo, CARD11-deficient mice fail to mount a T H 2 response capable of driving allergic inflammation 45 , whereas UNM mice show decreased frequency of FOXP3 + T reg cells and a gradual accumulation of T H 2 cells, resulting in allergic disease 31 . In contrast, we found that CARD11-mutated patients had normal numbers of T H 17 cells and T reg cells, although the patients' T reg cells appeared 'T H 2-like' on the basis of aberrant expression of GATA3, a recognized hallmark of atopic disease susceptibility 32 . Further study is required to confirm a causal role of this observation. These disparate findings underscore the importance of identifying and characterizing 'CARD11-opathies' in humans and mice. Indeed, BENTA patients harboring GOF CARD11 mutations show no signs of allergic disease, even though adoptively transferred T cells expressing constitutively active CARD11 can drive allergic disease in mice 46 .
Abnormal CARD11 signaling probably has intrinsic consequences for B cell fate as well. In contrast to the selective expansion of naive B cells seen in BENTA, we noted reduced numbers of CD19 + B cells in some CARD11 LOF patients. However, both GOF and LOF CARD11 mutations can reduce circulating memory B cells and affect immunoglobulin production in humans, suggesting that CARD11 is a critical gatekeeper for tuning proper BCR signals required for normal B cell maturation and differentiation 47 . Of interest here, although IgE signaling normally forces murine B cells to terminally differentiate into short-lived plasmablasts prone to apoptosis, loss of key BCR signaling molecules facilitates the survival and subsequent development of IgE + memory and long-lived plasma cells 48 . Our findings imply that attenuated CARD11 signaling may mirror this phenomenon in humans, permitting an atypical accumulation of longer-lived IgE-secreting plasma cells that promote allergic disease, particularly in childhood.
Additional work is required to identify the key pathogenic events related to the atopic phenotype and infection. Nevertheless, it may be that disease severity generally lessens over time, consistent with the phenotype in aged UNM mice (C. Goodnow, personal communication). Notably, our findings suggest that exogenous glutamine could partially correct specific defects in CARD11-mutant T cell responses, including proliferation and IFN-γ secretion. Glutamine supplementation has been explored as a treatment for reducing allergic disease in low-birth-weight infants, with a promising decrease in atopic dermatitis reported 49 . This simple therapeutic intervention may ameliorate disease in atopic patients harboring functional mutations in CARD11 or related genes by restoring normal glutamine uptake and mTORC1 signaling in activated T cells.
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